51³Ô¹ÏÍø

ExoPower enables in-motion wireless charging for mobile robots and forklifts—eliminating downtime and the need to over-purchase equipment for multi-shift operations. ExoPower solves a big problem for robot manufacturers by helping them meet their unit economic goals in this very competitive industry.

Current Capital Raise: $1.2 Million Pre-Seed
Contact: Curt Loomis, curt@expower.tech

Modendo develops ultra-thin fiber endoscopes—narrower than a human hair—that enable cellular-resolution imaging (<1 µm) in previously inaccessible regions of the body. These advanced probes transmit high-resolution images in real-time with a cross-area 10x smaller than the thinnest existing endoscopes. This addresses significant market needs in scientific research, disease diagnosis and medical treatment by reaching deep tissue targets with minimal invasiveness. With $2.5 million in non-dilutive funding raised to date, the company has achieved significant technical milestones, including the first in vivo experiment. Modendo is eligible to apply for NSF matching funds for up to 50% of a $1 million investment through the NSF SBIR/STTR Phase IIB Supplemental Funding program.

Current Capital Raise: $1 Million Pre-Seed
Contact: Antonio Miguel Caravaca Aguirre, Antonio.caravaca@modendo-inc.com

Ecovaleric is a 51³Ô¹ÏÍø-originated venture developing compostable, high-performance plastics from agricultural waste using clean electrochemistry. For brands and converters under pressure to meet sustainability goals, we offer a drop-in alternative that performs like traditional plastics—without tradeoffs in cost, strength, or scalability.

Current Capital Raise: $500,000 Pre-Seed
Contact: Roberta Leao, roberta@ecovaleric.com

LumenAstra is commercializing a non-invasive, wearable sensor that measures deep core body temperature several centimeters below the skin, regardless of its placement. The beachhead application is in measuring brain temperature in real-time during cardiac bypass surgeries that require cooling of the brain, decreasing mortality by up to 20%. Follow-on applications include early warning of heat stress and hypothermia, which claim thousands of fatalities for warfighters annually. LumenAstra has won seven highly competitive grant awards, securing $3.3 million in non-dilutive funding from the NSF, US Army and the State of Colorado's Advanced Industries program. With this current investment round, which complements $5 million in pending NIH and military grants, the company anticipates achieving FDA 510(k) submission and initial sales in Q4 2026.Ìý

Current Capital Raise: $5 Million Seed
Contact: Jim Pollock, jim@lumenastra.io

ImmunoLogic is creating therapies for inflammatory diseases, including Rheumatoid Arthritis, Multiple Sclerosis (MS) and ALS. The company is developing a novel oral prodrug targeted to inflammation and oxidative stress sites.

Current Capital Raise: $10 Million Pre-Seed
Contact: Stephen Collins, scollins@imlpharma.com